CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication

European Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2011, Pages 261-266

  Ward, Michael B ^a   Foster, David J R ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

CYP2C19; Dosing regimen; H. pylori eradication; Pharmacogenetics; Pharmacokinetics; Proton pump inhibitors

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; ERADICATION THERAPY; GENOTYPE; HELICOBACTER PYLORI; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRTUAL REALITY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; PROTON PUMP INHIBITORS; TISSUE DISTRIBUTION; ZOLLINGER-ELLISON SYNDROME;

EID: 79954436915     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0928-9     Document Type: Article

References (22)

1. UA Meyer 1996 Interaction of proton pump inhibitors with cytochromes p450: consequences for drug interactions Yale J Biol Med 69 3 203 209 1:CAS:528:DyaK2sXjs1Cht7Y%3D 9165689 (Pubitemid 27209693)
2. T Furuta Y Sagehashi N Shirai M Sugimoto A Nakamura M Kodaira K Kenmotsu M Nagano T Egashira K Ueda M Yoneyama K Ohashi T Ishizaki A Hishida 2005 Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H.pylori infection Clin Gastroenterol Hepatol 3 6 564 573 S1542356504007797 1:CAS:528: DC%2BD2MXmt1CqsLk%3D 10.1016/S1542-3565(04)00779-7 15952098 (Pubitemid 40824749)
3. BS Sheu AW Kao HC Cheng SF Hunag TW Chen CC Lu JJ Wu 2005 Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism Aliment Pharmacol Ther 21 3 283 288 10.1111/j.1365-2036.2005.02281.x 1:CAS:528:DC%2BD2MXit1ymurc%3D 10.1111/j.1365-2036.2005.02281.x 15691303 (Pubitemid 40278366)
4. Y Tanigawara N Aoyama T Kita K Shirakawa F Komada M Kasuga K Okumura 1999 CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by helicobacter pylori Clin Pharmacol Ther 66 5 528 534 10.1016/S0009-9236(99)70017-2 1:CAS:528:DyaK1MXotVCjt7c%3D 10.1016/S0009- 9236(99)70017-2 10579481
5. S Padol Y Yuan M Thabane IT Padol RH Hunt 2006 The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line ppi therapies: A meta-analysis Am J Gastroenterol 101 7 1467 1475 10.1111/j.1572-0241.2006.00717.x 1:CAS:528:DC%2BD28XotFKitLk%3D 10.1111/j.1572-0241.2006.00717.x 16863547 (Pubitemid 43980617)
6. M Kurzawski B Gawronska-Szklarz J Wrzesniewska A Siuda T Starzynska M Drozdzik 2006 Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients Eur J Clin Pharmacol 62 10 877 880 10.1007/s00228-006-0183-2 1:CAS:528:DC%2BD28XhtVeqsb%2FK 10.1007/s00228-006- 0183-2 16912869 (Pubitemid 44521437)
7. T Kita T Sakaeda N Aoyama T Sakai Y Kawahara M Kasuga K Okumura 2002 Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations Biol Pharm Bull 25 7 923 927 1:CAS:528:DC%2BD38XlvVChsLs%3D 10.1248/bpb.25.923 12132671 (Pubitemid 40022126)
8. T Furuta N Shirai F Xiao K Ohashi T Ishizaki 2001 Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome p4502c19 Clin Pharmacol Ther 70 5 484 492 S0009-9236(01)28055-2 1:CAS:528:DC%2BD38Xhslektw%3D%3D 10.1067/mcp.2001.119721 11719736 (Pubitemid 33135329)
9. M Saito N Yasui-Furukori T Uno T Takahata K Sugawara A Munakata T Tateishi 2005 Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes Br J Clin Pharmacol 59 3 302 309 10.1111/j.1365-2125.2004. 02329.x 1:CAS:528:DC%2BD2MXjtVOgu7Y%3D 10.1111/j.1365-2125.2004.02329.x 15752376 (Pubitemid 40388085)
10. T Furuta M Sugimoto N Shirai T Ishizaki 2007 CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor Pharmacogenomics 8 9 1199 1210 10.2217/14622416.8.9.1199 1:CAS:528:DC%2BD2sXhtlKhtrzJ 10.2217/14622416.8.9.1199 17924835 (Pubitemid 47578229)
11. T Furuta C Kodaira M Nishino M Yamade M Sugimoto M Ikuma A Hishida H Watanabe K Umemura 2009 [(13)c]-Pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole Aliment Pharmacol Ther 10.1111/j.1365-2036.2009.04044.x 19459830
12. JP Reilly 1999 Safety profile of the proton-pump inhibitors Am J Health Syst Pharm 56 suppl4 S11 S17 1:CAS:528:DC%2BD3cXhs1Sntw%3D%3D 10597119
13. N Torpey T Barker C Ross 2004 Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit Nephrol Dial Transplant 19 6 1441 1446 10.1093/ndt/gfh137 1:CAS:528: DC%2BD2cXkt1Sru70%3D 10.1093/ndt/gfh137 15004262 (Pubitemid 38786737)
14. T Niioka N Yasui-Furukori T Uno K Sugawara S Kaneko T Tateishi 2006 Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve Ther Drug Monit 28 3 321 325 10.1097/01.ftd.0000211835.18973.e3 1:CAS:528:DC%2BD28Xls1Kht7s%3D 10.1097/01.ftd.0000211835.18973.e3 16778714 (Pubitemid 44314917)
15. YR Hu HL Qiao QC Kan 2004 Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes Acta Pharmacol Sin 25 8 986 990 1:CAS:528:DC%2BD2cXmslaitbg%3D 15301728
16. HL Qiao YR Hu X Tian LJ Jia N Gao LR Zhang YZ Guo 2006 Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype Eur J Clin Pharmacol 62 2 107 112 10.1007/s00228-005-0063-1 1:CAS:528:DC%2BD28XivFSgsro%3D 10.1007/s00228-005-0063-1 16402242
17. C Dansirikul M Choi SB Duffull 2005 Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel® Comput Biol Med 35 5 389 403 1:CAS:528:DC%2BD2MXit1eqsrY%3D 10.1016/j.compbiomed.2004. 02.008 15767115 (Pubitemid 40354265)
18. KL Rost I Roots 1996 Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19 Hepatology 23 6 1491 1497 10.1002/hep.510230628 1:CAS:528:DyaK28Xkt1ensLc%3D 10.1002/hep.510230628 8675169 (Pubitemid 26181233)
19. AA Claessens ER Heerdink JT van Eijk CB Lamers HG Leufkens 2002 Determinants of headache in lansoprazole users in the Netherlands: results from a nested case-control study Drug Saf 25 4 287 295 10.2165/00002018-200225040- 00005 11994030 (Pubitemid 34569361)
20. BI Hirschowitz J Simmons J Mohnen 2005 Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study Clin Gastroenterol Hepatol 3 1 39 48 S1542356504006068 1:CAS:528:DC%2BD2MXht1KlsLg%3D 10.1016/S1542-3565(04)00606-8 15645403 (Pubitemid 40092942)
21. T Mizutani 2003 PM frequencies of major CYPs in Asians and Caucasians Drug Metab Rev 35 2-3 99 106 1:CAS:528:DC%2BD3sXlvVKgsb0%3D 10.1081/DMR- 120023681 12959412 (Pubitemid 37048293)
22. T Furuta K Ohashi T Kamata M Takashima K Kosuge T Kawasaki H Hanai T Kubota T Ishizaki E Kaneko 1998 Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Ann Intern Med 129 12 1027 1030 1:STN:280:DyaK1M%2FmsVyntg%3D%3D 9867757 (Pubitemid 29005826)